The University of Sheffield
Department of Infection and Immunity

Dr Paul Collini MBChB BSc MRCP DTM&H FHEA

Paul Collini

Academic Unit of Immunology and Infectious Diseases
Department of Infection and Immunity
L Floor
The University of Sheffield Medical School
Beech Hill Road
Sheffield
S10 2RX
UK

Tel: +44 (0)114 226 1113
Email: p.collini@sheffield.ac.uk
Fax: +44 (0)114 226 8898
Secretary - Jean Lazenby
Tel: +44 (0)114 271 2237
Email: j.lazenby@sheffield.ac.uk

Biography

I joined the University of Sheffield in 2006 as a Lecturer and Honorary Spr in Infectious Diseases (based at the Royal Hallamshire Hospital).

I qualified from Edinburgh University Medical School in 1998 and my general medical training was at St George's Hospital London.

I was involved in the roll out programme for ARV in Africa, setting up and running a clinic in Ghana from 2003-2005 while a clinical lecturer at the Kwame Nkrumah University of Science and Technology, Kumasi, Ghana.

I am currently an MRC clinical training fellow.

Research Interests

My research interest is in the innate immune response to pneumococcal infection in HIV, with a specific focus on the role of the macrophage. My MRC clinical training fellowship title is `The modulation of macrophage apoptosis during S. pneumoniae infection by HIV-1 or antiretroviral agents´.

I also have an ongoing interest in the roll out of antiretroviral treatment (ART) for HIV in resource-poor settings. Specifically, I continue to follow a closed cohort of Ghanaian HIV patients on ART in collaboration with researchers from the KNUST in Ghana and the James Cook University Hospital, Middlesbrough and Newcastle University in the UK.

Teaching Interests

I am a fellow of the Higher Education Academy and lecture on the MPH and MBChB courses at the University of Sheffield and the DTM&H at the Liverpool School for Tropical Medicine.

Key Publications

  1. Monocyte and macrophage dysfunction as a cause of HIV-1 induced dysfunction of innate immunity. Curr Mol Med. 2010 Nov 1;10(8):727-40.
  2. Inadvertent non-nucleoside reverse transcriptase inhibitor (NNRTI)-based antiretroviral therapy in dual HIV-1/2 and HIV-2 seropositive West Africans: a retrospective study. J Antimicrob Chemother. 2009 Sep;64(3):667-9.
  3. Successful use of miltefosine and sodium stibogluconate, in combination, for the treatment of an HIV-positive patient with visceral leishmaniasis: a case report and brief review of the literature. Ann Trop Med Parasitol. 2009 Jul;103(5):455-9.
  4. Sustained Immunological Responses to HAART at 36 Months in Ghanaian HIV Cohort, Clinical Infectious Diseases 2009; 48:988–91.
  5. Low prevalence of transmitted antiretroviral drug resistance in a large UK HIV-1 cohort J Antimicrob Chemother. 2008 Sep;62(3):464-8.
  6. GB virus C and HIV-1 RNA load in single virus and co-infected W. African individuals. AIDS.2006 Feb 14;20(3):379-386.